Files
Download Full Text (2.7 MB)
Publication Date
Spring 5-13-2025
Keywords
Cancer, Ewing Sarcoma, Hispidin, Eribulin Mesylate, Incucyte, Cancer Therapeutics, Pediatric Cancer
Description
Ewing sarcoma is a type of cancer that targets the cells within bones and soft tissue and is most prevalent in younger populations. It is important to look at this specific cancer because there is no cure yet, and the risks increase, even after a patient has completed their treatment. We hypothesize that if we treat Ewing sarcoma cell lines with natural compounds, specifically Hispidin and Eribulin Mesylate, then the cell lines will decrease in cell viability and there will be an increase in apoptosis of the cancerous cell lines. We performed a series of experiments, which included IC50 analysis, Caspase-3/7 analysis, and qRTPCR. Our results showed that there was cell inhibition for both Hispidin and Eribulin Mesylate, apoptosis was induced for both Hispidin and Eribulin Mesylate, and there were changes in gene expression for both Hispidin and Eribulin Mesylate. With our gathered data, we were able to prove our hypothesis was supported due to the decrease in viable cells, increase in apoptosis, and changes in gene expression.
Collection
Cell and Molecular Methods
Format
Medium
Lab report, poster
Size or Duration
12
City
San Antonio
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Mares, Elena; Juarrita, Angelina; Munoz, Sierra; and Shackleford, Terry Jo, "The Effects of Hispidin and Eribulin Mesylate on Cell Proliferation of Ewing Sarcoma Cell Lines" (2025). Cell and Molecular Methods. 6.
https://commons.stmarytx.edu/biostulab25/6